Peter Fong - Auckland Hospital;Healthpoint Limited

基本信息

Career Trajectory

Bio

Dr Fong is a Medical Oncologist specialising in Genitourinary Cancer especially Prostate cancer, Early Phase Oncology trials and still involved in Gynaecological Cancer management in private.
Peter is actively involved in the NZ Genitourinary Cancer Special Interest Group. He is an Honorary Academic at the Pharmacology Department, University of Auckland, continuing his interest in new cancer drugs development. He is a principal investigator in numerous clinical trials from Phase I to III. He has been published in major peer-reviewed journals.

Research Interests

Papers共 186 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Talazoparib Plus Enzalutamide in Hrr-Deficient Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Results from the Phase 3 Talapro-2 Trial

Karim Fizazi,Arun A. Azad,Nobuaki Matsubara,Joan Carles Galceran,André Poisl Fay,Ugo De Giorgi,Jae Young Joung,Peter C. C. Fong,Eric Voog,Robert J. Jones, Neal D. Shore,Curtis Dunshee,Stefanie Zschäbitz,Jan Oldenburg,Dingwei Ye,Xun Lin, Matko Kalac,A. Douglas Laird, Dana Kennedy, Nerraj Aggarwal

crossref（2025）

Cited0Views0Bibtex

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Silke Gillessen,Fabio Turco,Ian D. Davis,Jason A. Efstathiou,Karim Fizazi,Nicholas D. James,Neal Shore,Eric Small,Matthew Smith,Christopher J. Sweeney,Bertrand Tombal,Thomas Zilli,Neeraj Agarwal,Emmanuel S. Antonarakis,Ana Aparicio,Andrew J. Armstrong,Diogo Assed Bastos,Gerhardt Attard,Karol Axcrona,Mouna Ayadi,Himisha Beltran,Anders Bjartell,Pierre Blanchard,Maria T. Bourlon,Alberto Briganti,Muhammad Bulbul,Consuelo Buttigliero,Orazio Caffo,Daniel Castellano,Elena Castro,Heather H. Cheng,Kim N. Chi,Caroline S. Clarke,Noel Clarke,Johann S. De Bono,Maria De Santis,Ignacio Duran,Eleni Efstathiou,Onyeanunam N. Ekeke, Tamer I. H. El Nahas,Louise Emmett,Stefano Fanti,Omolara A. Fatiregun,Felix Y. Feng,Peter C. C. Fong,Valerie Fonteyne,Nicola Fossati,Daniel J. George,Martin E. Gleave,Gwenaelle Gravis,Susan Halabi,Daniel Heinrich,Ken Herrmann,Michael S. Hofman,Thomas A. Hope,Lisa G. Horvath,Maha H. A. Hussain,Barbara Alicja Jereczek-Fossa,Robert J. Jones,Anthony M. Joshua, Ravindren Kanesvaran,Daniel Keizman,Raja B. Khauli,Gero Kramer,Stacy Loeb,Brandon A. Mahal,Fernando C. Maluf,Joaquin Mateo,David Matheson, Mika P. Matikainen,Ray McDermott,Rana R. McKay,Niven Mehra,Axel S. Merseburger,Alicia K. Morgans,Michael J. Morris,Hind Mrabti,Deborah Mukherji,Declan G. Murphy,Vedang Murthy,Shingai B. A. Mutambirwa,Paul L. Nguyen,William K. Oh,Piet Ost,Joe M. O'Sullivan,Anwar R. Padhani,Chris Parker,Darren M. C. Poon,Colin C. Pritchard,Danny M. Rabah,Dana Rathkopf,Robert E. Reiter,Raphaele Renard-Penna,Charles J. Ryan,Fred Saad,Juan Pablo Sade,Shahneen Sandhu,Oliver A. Sartor,Edward Schaeffer,Howard I. Scher,Nima Sharifi,Iwona A. Skoneczna,Howard R. Soule,Daniel E. Spratt,Sandy Srinivas,Cora N. Sternberg,Hiroyoshi Suzuki,Mary-Ellen Taplin,Camilla Thellenberg-Karlsson,Derya Tilki,Levent N. Turkeri,Hiroji Uemura,Yuksel Urun,Claire L. Vale,Neha Vapiwala,Jochen Walz,Kosj Yamoah,Dingwei Ye,Evan Y. Yu,Almudena Zapatero,Aurelius Omlin

EUROPEAN UROLOGYno. 2 (2025): 157-216

Cited1Views0WOSBibtex

Exploration of Circulating Tumor Cell (CTC) Conversion and CTC0 As Prognostic Biomarkers for Efficacy in TALAPRO-2: Phase 3 Study of Talazoparib (TALA) + Enzalutamide (ENZA) Vs Placebo (PBO) + ENZA As First-Line (1L) Treatment in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc)

Steven Yip,Karim Fizazi,Douglas Laird,Nobuaki Matsubara,Arun Azad,Jae Young Joung,Peter C. C. Fong,Siska Van Bruwaene,Glenn Liu,Eric Voog,Cezary Szczylik,Jijumon Chelliserry,Cynthia G. Healy,Xun Lin,Neeraj Agarwal

Journal of Clinical Oncologyno. 16_suppl (2024): 5023-5023

Cited0Views0Bibtex

1975P Avelumab First-Line (1L) Maintenance in Advanced Urothelial Carcinoma (auc): Conditional Survival and Long-Term Safety in Patients (pts) Treated for ≥1 or ≥2 Years in JAVELIN Bladder 100

P. Grivas, S.H. Park,E. Voog,W-P. Su,W. Demey,P.C. Fong, J.A. Garcia, N. Jacob, A. Gerhold-Ay,K. Tyroller, J. Hoffman,J. Bellmunt,T.B. Powles

Annals of Oncology (2024): S1144

Cited0Views0Bibtex

Coformulation of Pembrolizumab and Vibostolimab in Patients (pts) with Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer (mcrpc): KEYNOTE-365 Cohort G

Peter C. C. Fong,Mariusz Kwiatkowski,Alessandra Mosca,Begona Perez Valderrama, Yi-Hsiu Huang,Ahmed H. Zedan, Kamil Kuc,Pawel Wiechno,Brigitte Laguerre,Enrique Gonzalez-Billalabeitia, Mikhail Osipov, Didem Sener Dede,Jeffrey Goh,Gedske Daugaard, Pengfei Zhu,Kentaro Imai,Yingjie Liu,Jose Angel Arranz Arija

Journal of Clinical Oncologyno. 4_suppl (2024): 149-149

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn